vs
Mastech Digital, Inc.（MHH）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Mastech Digital, Inc.的季度营收约是REGENXBIO Inc.的1.5倍（$45.5M vs $30.3M），Mastech Digital, Inc.净利率更高（2.1% vs -221.3%，领先223.5%），REGENXBIO Inc.同比增速更快（43.0% vs -10.4%），Mastech Digital, Inc.自由现金流更多（$4.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -1.5%）
Mastech Digital, Inc.是一家专注数字化转型与信息技术服务的企业，总部位于美国宾夕法尼亚州匹兹堡，业务覆盖北美、中东、亚洲及日本地区，为各行业企业提供专业IT相关解决方案与服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MHH vs RGNX — 直观对比
营收规模更大
MHH
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出53.4%
-10.4%
净利率更高
MHH
高出223.5%
-221.3%
自由现金流更多
MHH
多$57.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-1.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.5M | $30.3M |
| 净利润 | $972.0K | $-67.1M |
| 毛利率 | 28.3% | — |
| 营业利润率 | 2.2% | -190.0% |
| 净利率 | 2.1% | -221.3% |
| 营收同比 | -10.4% | 43.0% |
| 净利润同比 | 227.3% | -31.2% |
| 每股收益（稀释后） | $0.08 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MHHRGNX
| Q4 25 | $45.5M | $30.3M | ||
| Q3 25 | $48.5M | $29.7M | ||
| Q2 25 | $49.1M | $21.4M | ||
| Q1 25 | $48.3M | $89.0M | ||
| Q4 24 | $50.7M | $21.2M | ||
| Q3 24 | $51.8M | $24.2M | ||
| Q2 24 | $49.5M | $22.3M | ||
| Q1 24 | $46.8M | $15.6M |
净利润MHHRGNX
| Q4 25 | $972.0K | $-67.1M | ||
| Q3 25 | $941.0K | $-61.9M | ||
| Q2 25 | $135.0K | $-70.9M | ||
| Q1 25 | $-1.4M | $6.1M | ||
| Q4 24 | $297.0K | $-51.2M | ||
| Q3 24 | $1.9M | $-59.6M | ||
| Q2 24 | $1.4M | $-53.0M | ||
| Q1 24 | $-161.0K | $-63.3M |
毛利率MHHRGNX
| Q4 25 | 28.3% | — | ||
| Q3 25 | 27.8% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 26.7% | — | ||
| Q4 24 | 29.0% | 70.2% | ||
| Q3 24 | 28.5% | 48.8% | ||
| Q2 24 | 28.2% | 52.5% | ||
| Q1 24 | 25.9% | 72.6% |
营业利润率MHHRGNX
| Q4 25 | 2.2% | -190.0% | ||
| Q3 25 | 1.7% | -176.3% | ||
| Q2 25 | 0.1% | -296.3% | ||
| Q1 25 | -3.8% | 13.6% | ||
| Q4 24 | 0.1% | -242.1% | ||
| Q3 24 | 4.7% | -256.6% | ||
| Q2 24 | 3.4% | -251.3% | ||
| Q1 24 | -0.9% | -408.8% |
净利率MHHRGNX
| Q4 25 | 2.1% | -221.3% | ||
| Q3 25 | 1.9% | -208.3% | ||
| Q2 25 | 0.3% | -331.8% | ||
| Q1 25 | -3.0% | 6.8% | ||
| Q4 24 | 0.6% | -241.3% | ||
| Q3 24 | 3.6% | -246.3% | ||
| Q2 24 | 2.8% | -237.7% | ||
| Q1 24 | -0.3% | -405.4% |
每股收益（稀释后）MHHRGNX
| Q4 25 | $0.08 | $-1.30 | ||
| Q3 25 | $0.08 | $-1.20 | ||
| Q2 25 | $0.01 | $-1.38 | ||
| Q1 25 | $-0.12 | $0.12 | ||
| Q4 24 | $0.01 | $-0.99 | ||
| Q3 24 | $0.16 | $-1.17 | ||
| Q2 24 | $0.12 | $-1.05 | ||
| Q1 24 | $-0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $36.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $89.3M | $102.7M |
| 总资产 | $111.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MHHRGNX
| Q4 25 | $36.5M | $230.1M | ||
| Q3 25 | $32.7M | $274.2M | ||
| Q2 25 | $27.9M | $323.3M | ||
| Q1 25 | $24.7M | $267.9M | ||
| Q4 24 | $27.7M | $234.7M | ||
| Q3 24 | $23.9M | $255.5M | ||
| Q2 24 | $20.6M | $290.4M | ||
| Q1 24 | $19.4M | $338.7M |
股东权益MHHRGNX
| Q4 25 | $89.3M | $102.7M | ||
| Q3 25 | $88.0M | $161.5M | ||
| Q2 25 | $87.8M | $213.7M | ||
| Q1 25 | $86.9M | $274.2M | ||
| Q4 24 | $87.4M | $259.7M | ||
| Q3 24 | $86.5M | $301.4M | ||
| Q2 24 | $84.0M | $348.3M | ||
| Q1 24 | $81.7M | $390.7M |
总资产MHHRGNX
| Q4 25 | $111.8M | $453.0M | ||
| Q3 25 | $112.6M | $525.2M | ||
| Q2 25 | $110.4M | $581.0M | ||
| Q1 25 | $110.1M | $490.9M | ||
| Q4 24 | $111.5M | $466.0M | ||
| Q3 24 | $111.5M | $519.1M | ||
| Q2 24 | $107.5M | $569.4M | ||
| Q1 24 | $106.1M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $4.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 9.5% | -174.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.48× | — |
| 过去12个月自由现金流最近4个季度 | $10.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MHHRGNX
| Q4 25 | $4.4M | $-52.3M | ||
| Q3 25 | $6.5M | $-56.0M | ||
| Q2 25 | $3.3M | $-49.3M | ||
| Q1 25 | $-3.0M | $33.6M | ||
| Q4 24 | $4.0M | $-31.6M | ||
| Q3 24 | $3.3M | $-40.5M | ||
| Q2 24 | $1.2M | $-45.5M | ||
| Q1 24 | $-1.3M | $-55.5M |
自由现金流MHHRGNX
| Q4 25 | $4.3M | $-52.8M | ||
| Q3 25 | $6.3M | $-56.5M | ||
| Q2 25 | $3.2M | $-49.7M | ||
| Q1 25 | $-3.1M | $32.6M | ||
| Q4 24 | $3.9M | $-32.7M | ||
| Q3 24 | $3.2M | $-40.9M | ||
| Q2 24 | $707.0K | $-46.0M | ||
| Q1 24 | $-1.6M | $-56.0M |
自由现金流率MHHRGNX
| Q4 25 | 9.5% | -174.0% | ||
| Q3 25 | 13.0% | -189.9% | ||
| Q2 25 | 6.6% | -232.8% | ||
| Q1 25 | -6.4% | 36.6% | ||
| Q4 24 | 7.7% | -154.2% | ||
| Q3 24 | 6.2% | -168.9% | ||
| Q2 24 | 1.4% | -206.2% | ||
| Q1 24 | -3.4% | -358.5% |
资本支出强度MHHRGNX
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 0.2% | 5.1% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 1.0% | 2.1% | ||
| Q1 24 | 0.6% | 3.6% |
现金转化率MHHRGNX
| Q4 25 | 4.48× | — | ||
| Q3 25 | 6.88× | — | ||
| Q2 25 | 24.41× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 13.60× | — | ||
| Q3 24 | 1.76× | — | ||
| Q2 24 | 0.85× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MHH
| IT Staffing Services | $37.6M | 83% |
| Data And Analytics Services | $7.8M | 17% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
